Steroid-sparing strategies for managing ICI-induced arthritis: safety and oncological outcomes
Authors' conclusion
DMARDs offer a safe and effective steroid-sparing strategy for ICI-induced arthritis, preserving cancer treatment efficacy.
Study context
- Population
- Patients with ICI-induced arthritis treated at one centre, January 2019-January 2024 (68% male, mean age 69.5 years)
- Participants
- 31 patients
- Exposure
- Glucocorticoid (GC) plus csDMARD or bDMARD vs GC only
- GC+DMARDn = 18
- Outcome
- Steroid-sparing effect of DMARDs (cumulative steroid use)
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Cumulative steroid use
- DMARD-treated patients had significantly lower cumulative steroid use
- GC+DMARD vs GC-only: P = 0.047
Observational data: associations, not effects.
Secondary outcomes
| Outcome | GC+DMARD |
|---|---|
| Timing of DMARD initiation from onset of ICI-induced arthritis | |
| Within 2 months | 61% |
| Within 4 months | 72% |
- Time to cancer progression · no adverse impact
- P = 0.27
Time to cancer progression
- No adverse impact of DMARDs on time to cancer progression
Original publication
Steroid-sparing strategies for managing ICI-induced arthritis: safety and oncological outcomes. Clin Exp Rheumatol. Published 12 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →